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Depression is one of the most common mental disorders and numerous medications are used to reduce the psychotic 
symptoms.  
The aim of this study was to evaluate the therapeutic effects of two commonly used antidepressant drugs, including 
Fluoxetine (Flx) and Imipramine (IMP) to improve depressive-like behaviors as well as the activity of hypothalamic 
pituitary-adrenal cortex (HPA). 
Methods: Initially, 40 adult male albino rats weighing 25±5g were selected for this experimental study. The animals 
were kept or housed in separate cages under standard temperature (25±1°C) and light-dark conditions (12 hours 
light/dark cycle). Rats were divided into four groups: each group containing 10 rats, control, immobility stress, Flx 
receiver, and IMP receiver. Polyethylene restrainer was used to induce immobility stress for 14 days. Finally, the pa-
rameters of IMT, ST, serum levels of corticosterone and glucose were evaluated in all four mentioned groups. 
Results: The results showed that the patient group's immobility time (IMT) increased compared to the control group, 
but the patient group's swimming time (ST) decreased compared to the control group. The effect of immobility stress on 
IMT, ST, corticosterone, and glucose factors in the patient group was increasing, increasing, decreasing, and decreas-
ing, respectively, whereas the effect of Flx drug on these mentioned factors was decreasing, increasing, increasing, and 
increasing, respectively, while the effect of IMP on all mentioned factors was decreasing, increasing, decreasing, and 
increasing, respectively. 
Conclusion: Based on the results, it can be concluded that the antidepressant Flx and IMP drugs have various effects 
on the HPA activity, and the application of immobility stress causes depressive-behavior. Moreover, Flx is more effec-
tive than IMP in the treatment of depressive behaviors 
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1. Introduction  
Depression is a mental disorder that leads people 
to feel depressed and completely disinterested for the 
majority or all of the time [1]. Certainly, most healthy 
individual feel sad from time to time or on occasion, 
which is the body's natural response to life's problems; 
but, if sadness persists for an extended period of time, it 
may lead to disappointment, loss of desire or motivation 
to live, and depression [2]. Furthermore, depression is 
often related to reduced attention or impaired focus, 
mental retardation, guilt feelings and eventually followed 
by thoughts of death [3]. There are many factors that 
contribute to depression, but the most important are psy-
cho-biological factors (including serotonergic neuro-
transmission, norepinephrine, dopamine, and genetics); 
social-psychological factors (like different life events); 
and internal stressors (such as changes in serum choles-
terol levels, triglycerides, blood glucose and coagulation 
factors) [4]. More than half of patients between the ages 
of 20 and 50 are participating in the community, and two-
thirds of patients have suicidal thoughts, with 10–15 % 
committing suicide [5].  
As per previous studies, stress and adversity in 
life are the most significant factors to intensify depres-
sion in humans. Unexpected stress factors induce chang-
es in behavioral parameters such as physical, sensorial, 
and mental activity, eating disorders, and sexuality in 
animals, much as they do in humans [6]. According to 
published studies, stress stimulates the release of cortico-
steroids from the adrenal cortex and thus causes depres-
sion through dysfunction of the hippocampus. Decreased 
serotonin or norepinephrine synaptic levels in different 
parts of the brain, such as the frontal cortex, and also 
decreased production of brain-derived neurotrophic fac-
tor in the hippocampus may also contribute to stress-
induced depression [7]. Moreover, a decrease in seroto-
nin or norepinephrine synaptic levels in various areas of 
the brain, such as the frontal cortex, as well as a decrease 
in brain-derived neurotrophic factor activity in the hippo-
campus, may also lead to stress-induced depression  




[6, 7]. It was confirmed by previous studies that the de-
crease in serotonin and norepinephrine in the brain caus-
es depression [8–11].  
Tricyclic antidepressants (TCAs) and selective 
serotonin reuptake inhibitors (SSRIs) are two availa-
ble drug therapies that affect the neurotransmitters as 
mentioned above [9, 10]. The drug fluoxetine (Flx) with 
the scientific name (N-methyl-3-phenyl-3-[4-
(trifluoromethyl) phenoxy] propan-1-amine, and under 
the trade or brand name "Prozac" is one of the 
SSRIs used to treat neurological disorders such as de-
pression and anxiety [9–11]. For the first time in 1986, 
an American pharmaceutical company (Eli Lilly) pro-
duced structurally formulated fluoxetine (Flx), and then 
introduced for use in the United States a year later to 
treat depression [12]. Fluoxetine blocks serotonin 
reuptake in neurons by inhibiting the action of the sero-
tonin transporter (SERT) [13].  
The history of imipramine (IMP) use is much old-
er than selective serotonin reuptake inhibitors (SSRIs), 
and the history of production, evaluation, and use of 
imipramine dates back to 1955–1950. Imipramine  
(3-(10,11-dihydro-5H-dibenzo [b, f] azepin-5-yl) -N, N-
dimethylpropan-1-amine) is a class of tricyclic antide-
pressants (TCAs) and it has a beneficial effect on the 
treatment of depression and its function is to inhibit the 
re-absorption of serotonin or norepinephrine, as a result 
of which the amount of these neurotransmitters in the 
synaptic cleft increases [14].  
Flx and IMP have been shown to have antidepres-
sant effects in previous studies. Antidepressants have 
also been shown in animal models to be effective in 
reducing immobility in rodents and, as a result, depres-
sive symptoms [5]. Akhondzadeh et al. (2004) reported 
that the effect of saffron extract with imipramine (as a 
common antidepressant used to manage mild to moderate 
depression), and showed that IMP decreases depressive 
symptoms despite side effects [15].  
According to Chen et al. (2007) study, tricyclic anti-
depressants (TCAs) can induce hyperglycemia and hyperin-
sulinemia in rats, while SSRIs decreased blood glucose in 
rats [16]. Researchers have carried out studies on herbal 
antidepressants to replace chemical antidepressants because 
of their side effects, and the results have been reported to be 
acceptable. For example, the results of a study by Hajra-
souliha and Khakpour (2020) showed that Melissa offici-
nalis hydro-alcoholic extract is similar to Flx and reduces 
depression [17]. In a study by Shafei et al. (2018), who 
showed that Viola odorata decreases depressive symptoms 
in the same way that both Flx and IMP [18].  
Due to the fact that each antidepressant 
has different effects, mechanisms, and side effects. In 
addition, long-term antidepressant chemical use can 
result in more side effects. Therefore, a medication with 
higher efficacy properties and fewer side effects is neces-
sary [19]. Because of the above reasons, the main pur-
pose of this study was to evaluate study was to evaluate 
the efficacy of two well-known antidepressants, fluoxe-
tine and imipramine (Fig. 1) in decreasing symptoms 
associated with depressive behaviors, as well as their 
impact on the hypothalamic-pituitary-adrenal cortex 




Fig. 1. The molecular structure of fluoxetine and imipramine 
 
2. Planning (methodology) of the research 
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3. Material & Methods 
Ethical consideration. The present study was 
submitted to and approved by the animal ethics frame-
work under the supervision of the Institute for the Pre-
vention of Cruelty to Animals and Research Council. 
Moreover, it was ethically approved by the ethical coun-
cil of research of the Al-esraa university college, Iraq 
(456/lq) on 12.10.2020. The European Council Directive 
(2010/63/EU) recommendations of September 22, 2010, 
regarding the standards in protecting animals used for 
experimental purposes, was also followed.  
Animals.This study was conducted in the labor-
atories of the Department of pharmacy, Al- esraa uni-
versity college in 2021 year. Initially, 40 adult male 
albino rats weighing 25±5 g were selected for this ex-
perimental study. The animals were kept or housed in 
separate cages under standard temperature (25±1 °C) 
and light-dark conditions (12 hours light/dark cycle).  
Throughout this time, the animals were given com-
mercial water and food in sufficient quantities without 
limits, and each animal was only used once. The ethi-
cal standards of working with laboratory animals were 
observed throughout the experiment, and all experi-
ments were performed throughout the lighting time. A 
digital balance (accuracy 0.01) was used to weigh the 
animals. 
Control and patient groups. In this study,  
40 rats were randomly classified into 4 groups: healthy 
control, patient or disease control, patient 
groups receiving Flx medication, and disease groups 
receiving IMP drugs. Group 1: Healthy control group, 
rats in this group was given only 0.2 mL distilled water 
intraperitoneal (IP) for 14 days. Group 2: Patient control 
group, rats in this group were in fact immobilized stress, 
rats taken only 0.2 mL distilled water IP for 14 days 
Group 3 (patient group taking Flx drugs): Rats under 
immobilized stress were given 20 mg/kg body weight Flx 
drug (dissolved in distilled water) via IP for 14 days. 
Group 4: the fourth group is similar to the third, but in-
stead of Flx drug, they were given 30 mg/kg IMP (dis-
solved in distilled in water) using IP for 14 days (Fig. 3). 
The amount and method of administering drugs to con-
trol and patient rats were based on previous simi-
lar studies [17–19]. 
 
 
Fig. 3. The procedure of dividing the control and patient groups 
 
Forced swimming test (FST). One of the most 
common tests to evaluate the antidepressant activity of 
drug compounds is the forced swimming test (FST) [20, 
21]. In this test, immobility time, depressive equivalents 
and reduction of this time equivalent to antidepressant 
effect was considered. After injecting Flx, IMP drugs or 
distilled water separately in a condition with 25×25×25 cm 
distance containing water at 25±1 °C was considered. 
Immobility time was usually defined as the lack of limb 
and foot movements, while swimming time was defined 
as the rotational movements of the animal around the 
container. The whole test lasted 6 minutes, the first  
2 minutes used to allow the animal to adapt to its envi-
ronments, and the remaining 4 minutes used to monitor 
and record each immobility and swimming response in 
seconds using a stopwatch [18–21].  
Tail suspension test (TST). The tail suspension 
test (TST) is another typical test used to measure the 
antidepressant effect of drug compounds after the FST. 
For this purpose, two metal bases with a height of 70 cm 
were used and a 50 cm long string was installed between 
the two metal bases. The rat tail was tied and protect with 
a strap. The test then started with a quick and 
sharp movement of the rat. Thereafter, the rats that were 
hung from the tail were totally immobile, inactive, and 
unresponsive, and this time was considered as immobili-
ty time. In this test, as in FST, the immobility time, de-
pressive equivalents and reduction of time equivalent to 
antidepressant effect was recorded by a stopwatch in 
seconds. The overall test time was 6 minutes; the first  
2 minutes were used to allow the animal to adapt to the 
environment, and the next 4 minutes were used to record 
the immobility time [17–19]. 
Immobilization Stress (IST). A polyethylene re-
strainer was used to apply immobility stress, allowing the 
rats to lose their mobility as much as possible. Pores 
were also made in the body of the restrainer for air condi-
tioning. For 14 days, rats were housed or kept at a specif-
ic time of day (8–10 am) to avoid other stress factors 
such as noise, light changes, and temperature changes as 
much as possible. The rats were returning to their cages 
in groups of ten after being stressed [19, 22].  
Corticosterone and glucose measurement. After 
TST was completed, all animals were weighed using a 
scale and then anaesthetized with ether. After anesthesia, 
the chest was dissected from the xiphoid region of the 




sternum by incision of the diaphragm. Then, a blood 
sample was collected directly from the animal's heart 
using a 5 ml syringe, and the samples were centrifuged 
(for 15 minutes at 3000 rpm). The serum was separated 
and stored at –20 °C until corticosterone and glucose 
levels were determined. 
Corticosterone was measured using an ELISA kit 
(according to the kit instructions). Also, according to 
previous studies, the glucose (GOD-PAP) method was 
used to measure serum glucose [23]. In this method, the 
glucose oxidase enzyme causes oxidation of glucose and 
production of H2O2 in the presence of peroxidase, para-
aminophenazone, and phenol, resulting in a pink com-
plex color and absorption at 500 nm. 
The amount of glucose in the sample determines 
the amount of color-complex formation and, as a result, 
the amount of absorption. In fact, the glucose-measuring 
kit includes two reagents: the first reagent contains all the 
components of the above two reactions and the second 
reagent is a standard glucose solution with a concentra-
tion of 100 ml/dL, with a glucose concentration of up to 
400 mg/dL in this form. Follows Beer-Lambert's law 
(absorption measured by a spectrophotometer is directly 
related to concentration [19, 23].  
Statistical analysis. The various parameters like 
immobility time (IMT), swimming time (ST), serum corti-
costerone, and serum glucose levels in healthy control 
groups were compared to other different group patients 
(recipients of Flx, IMP, and distilled water) using a one-
way ANOVA test at a significant level (α= 0.05).  
 
4. Results 
The results showed that the application of immo-
bility stress to the patient group significantly increased 
the immobility time compared to the control group 
(144.2 compared to 91.9 seconds) (p<0.05). Moreover, 
the results showed that administration of Flx to the pa-
tient group significantly reduced the immobility time 
from 144.2 to 70.7 seconds (p<0.05), while administra-
tion of IMP reduced the mentioned time, it was from 
144.2 to 128.6 seconds, which was not statistically sig-
nificant (P> 0.001) (Fig. 3, 4, Tables 1, 2).  
The results of the present study showed that the 
mean ST in the control group, the patient group receiving 
Flx and the patient group receiving IMP were 28.6±3.1, 
172.7±12.2 and 38.8±5.9, respectively (Fig. 3, 5). The 
results of this section of the study revealed that the ST 
differences between the control and the IMP groups were 
not significant (p>0.05), but they were significant 
(p˂0.001) between the control and the Flx group 
(p<0.001) (Table 1).  
Immobilization stress and administration of Flx 
and IMP caused a significant decrease (p<0.05) in serum 
corticosterone levels compared to the control group. 
Based on the results, administration of Flx to animals 
under immobility stress caused a significant increase in 
serum corticosterone levels compared to the stressed 
group who did not receive this drug (p<0.001). 
As opposed to the effect of Flx, there was no sig-
nificant difference in serum corticosterone levels in the 
stressed groups with and without IMP (P>0.001) (Fig. 3, 6, 
Table 1).  
The finding of this research revealed that immo-
bility stress significantly reduced the patient group's 
serum glucose level (34.2 g/dl) as comparison to the 
control group's (88.4 g/dl) (p>0.001). However, when 
Flx and IMP were given to immobilize stressed rats, 
there was no significant difference in serum glucose 
levels between the control and stressed rats (p>0.001) 
(Fig. 3, 7, Table 1).  
 
Table 1 
The IMST, ST, corticosterone and glucose in various studied groups 











128.6±6.7**** 70.7±6.2*** 144.0±9.8** 91.9±8.1* Mean ± SD 
IMT (S) 115.9 62.8 127.3 80.2 Min 
135.7 82.4 156.3 103.4 Max 
38.9±5.9 172.7±12.2*** 36.7±4.7 28.6±3.1* Mean ± SD 
ST (S) 29.7 160.4 31.9 25.1 Min 
44.1 192.9 44.7 34.5 Max 
0.51±0.06**** 2.22±0.13*** 0.61±0.05 4.73±0.37* Mean ± SD 
Corticosterone 
(µg/dl) 
0.44 2.05 0.51 4.1 Min 
0.62 2.45 0.67 5.2 Max 
64.1±2.9**** 55.6±5.7*** 34.2±2.3 88.4±3.7* Mean ± SD 
Glucose (µg/dl) 59.9 48.4 30.4 82.3 Min 
68.9 63.7 38.3 93.5 Max 
Note: * – p<0.05 compared to the CWOD group with other groups, ** – P<0.05 compared to the PWOD group with other groups; 
*** – p<0.05 compared to the PWFD group with other groups; **** – p<0.05 compared to the PWID group with other groups;  
SD – Standard deviation; Min – Minimum; Max – Maximum; CWOD – Control group without drugs; PWOD – Patient group with-
out drugs; PWFD – Patient group with Flx drug; PWID – Patient group with IMP drug 
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Fig. 5. Comparison of the swimming time between studied groups 
 
 
Fig. 6. Comparison of the corticosterone amount between studied groups 
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5. Discussion  
The main purpose of this study was to evaluate 
the effect of Flx and IMP drugs on factors such as immo-
bility time (IMT), swimming time (ST) as well as serum 
corticosterone and glucose levels (FST) and the tail sus-
pension test (TST), both of which are time-based viewing 
in an inescapable position, are two common tests for 
antidepressant activity compounds, after initial attempts 
to escape, the rats quickly accept immobility. Research-
ers believe that this change in behavior (immobility) 
reflects the behavior of depression [24]. 
The results of the current research revealed that 
immobility stress causes depressive-like behavior in the 
patient group. However, Flx and IMP injection reduced 
depressive-like behavior, with Flx being significantly 
more effective than IMP. The findings of this research 
were in accordance with those of several related studies 
but not with others. In Bayramlou et al. (2018) study, 
who was reported that in the immobility stress model (for 
14 days), administration of Flx or IMP reduces immobili-
ty time [19]. Also, Liu et al. (2016) used a model of 
chronic immobility stress (21 days) to prove that the 
immobility time in forced swimming test increases in 
stressed animals [25]. In some recent studies, depressive-
like behavior due to persistent or chronic immobility 
stress has been reported in rodents [26] which is similar 
with the findings of TST and FST in the present study. 
However, some studies have not confirmed such behav-
ioral changes after chronic immobility stress [27]. The 
reasons for this difference can be linked to the character-
istics of immobile stress (such as repetition and stress 
time) [28]. Since serotonin is the biogenic neurotransmit-
ter most associated with depression, a reduction in synap-
tic serotonin in the patient group may be one of the caus-
es for depressive-like behavior, as long-term stress has 
been shown to decrease serotonin release in some brain 
structures [29]. Therefore, it can be assumed that with a 
high probability, a decrease in serotonin in the brain caus-
es depression and in more severe cases, Alzheimer's dis-
ease [8]. Sirisha et al. (2014) found that chronic (7–day) IP 
injection of Flx at standard doses of 10 and 20 mg/L in 
rats decreased immobility time in TST [30]. Nagasawa et 
al. (2014) reported that oral administration of IMP  
(10 mg / kg) for 28 days reduced the immobility time in 
depressed rats [31]. Therefore, since Flx and IMP are 
among the drugs that influence the serotonergic system 
and prevent the reabsorption of serotonin at presynaptic 
ends, this effect may clarify their antidepressant effects. 
That it increases the inhibition of serotonin reuptake in 
nerve synapses and reduces depressive symptom [19].  
The findings regarding changes in serum corti-
costerone and glucose levels showed that the application 
of immobility stress for 14 days caused a significant 
decrease in these indicators compared to the control 
group. In this regard, reports indicate that stressful stimu-
li increase the secretion of corticotrophin-releasing hor-
mone (CRH) from the Para-ventricular nerve nucleus of 
the hypothalamus, and this neurohormone has a stimula-
tory effect on the anterior pituitary gland, secretion of 
adrenocorticotropic hormone (ACTH), and this hormone 
also increases the secretion of corticosterone from the 
cortical part of the adrenal glands in rats [32]. However, 
some studies have shown that when animals are repeat-
edly exposed to stress factors, some of the behavioral and 
physiological effects of the exposure are decreased, and 
the animals become to get the habit to the stress factors; 
for example, corticosterone or ACTH levels decrease 
after repetitive exposure to stress [33]. As a result, one of 
the causes for the reduction in corticosterone in the cur-
rent study was the persistence of immobility stress and 
hence the animal's habituation to the stress factors. On 
the other hand, reports suggest that glucocorticoids pro-
duced by the Hypothalamic–pituitary–adrenal axis 
(HPA) as a result of stress usually increase gluconeogen-
esis activity and lead to elevated blood glucose levels 
[34]. Therefore, according to these findings, the decrease 
in blood glucose levels in stressed or depressed animals 
compared to the control group can be explained and 
related to the decrease in serum corticosterone levels. 
Since Flx administration increased corticosterone levels 
compared to the patient group in the current study, but 
IMP administration has little effect on serum corti-
costerone levels compared to the patient group. Since 
studies have shown that Flx and other Flx drugs, as well 
as other SSRIs, increase hypothalamic secretion and 
stimulate the HPA axis, Flx tends to increase corti-
costerone levels by increasing HPA axis activity [35], 
which in turn causes the secretion of catecholamine. 
Frost et al. (2003) found that chronic IMP treatment of 
depressed individuals could modulate HPA axis activity, 
meaning that the HPA axis could be an effective target 
for antidepressant efficacy [36]. Other research has 
shown that IMP increases the expression of glucocorti-
coid (GR) receptor genes in areas of the brain connected 
to negative HPA-axis feedback in the early stages [37] 
and all of these findings support the fact that this group's 
corticosterone levels are lower than the control groups. 
Antidepressant treatment for depressive and diabetic 
patients with mental disorders has since been shown to 
be one of the most effective ways to increase blood glu-
cose control and improve mood [38].  
Most antidepressants increase serotonin and nore-
pinephrine monoaminergic levels, thereby controlling or 
regulating the activity of HPA, which is associated with 
major depression and insulin resistance syndrome [39]. 
Research has also shown that cerebral serotonin is in-
volved in regulating plasma glucose levels, and that elec-
tric shock to raphe nuclei leads to a hyperglycemic re-
sponse, while destruction of serotonergic fibers by spe-
cific neurotoxic agents disrupts hyperglycemia due to 
electric shock in raphe nuclei [40].  
Antidepressants, on the other hand, are believed to 
cause hyperglycemia either by inhibiting the insulin 
signalling cascade, which leads to insulin resistance, or 
by interfering with the HPA axis, which leads to insulin 
resistance. Antidepressants, in fact, can induce hypergly-
cemia by raising cortisol levels, which causes insulin 
resistance. Antidepressants, on the other hand, can in-
duce hypoglycemia by increasing insulin sensitivity [41].  
Therefore, in the present study, it seems that the 
increase in serum glucose as a result of Flx or IMP com-
pared to the patient group was related to the increase in 
synaptic serotonin or inhibition of insulin signalling 
cascade. It is also thought that Flx (due to its additive 
effect on serum corticosterone levels compared to the 
patient group in the present study) caused insulin re-




sistance by increasing corticosterone levels and thus 
increased glucose levels compared to the patient group.  
Although the antidepressant effects of Flx and 
IMP were compared in the current study, and the degree 
of depressive-like behaviors after long-term administra-
tion of these drugs in a depressed model due to immobili-
ty stress was evaluated, further research is required in 
this area. Concurrently, the impact of these medications 
on the hypothalamic-pituitary-adrenal cortex axis (HPA) 
and, as a result, glucose levels in depressive models 
should be studied. 
Study limitations. Due to financial constraints, it 
was not possible to test more laboratory animals. In addi-
tion, only twice analysis of the desired compounds were 
performed in the blood of different groups. 
Prospects for further research. To achieve bet-
ter results for use to protect human health, the results of 
this animal study and other similar studies must be trans-
lated into human-applicable results. To do this, uncer-
tainty factors (safety factors) must be used. These factors 
are used because of the differences in the metabolism of 
the human and animal bodies and the extrapolation of 
animal-to-human data. 
 
6. Conclusion  
The results showed that the patient group's immo-
bility time was significantly increased than the control 
groups (144.2 compared to 91.9 seconds). However, in 
comparison to the patient group, immobility time was 
decreased by fluoxetine (144.2 to 70.7 seconds) and 
imipramine administration (144.2 to 128.6 seconds). 
Immobilization stress decreased serum corticosterone 
and glucose levels significantly compared to control 
group (P>0.001), fluoxetine administration increased 
corticosterone levels compared to the patient group, but 
imipramine administration had no change. In comparison 
to the patient group, fluoxetine or imipramine admin-
istration increased glucose levels. Based on the current 
results, it can be concluded that different antidepressants 
have different effects on improving depressive behaviors 
and hypothalamic-pituitary-adrenal cortex axis 
(HPA) activity, which may be due to factors such as 
different mechanisms of these drugs, as well as dosage 
and therapeutic time. Finally, it can be concluded that 
fluoxetine is more effective than imipramine at reducing 
depressive-like behavior. 
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